title: Dyslipidemia can be controlled in diabetic as well as nondiabetic recipients after kidney transplant.
abstract: BACKGROUND
  Patients with diabetes have been reported to have greater dyslipidemia after kidney transplant (KTX). Because postKTX management of diabetes has changed markedly since those reports, we hypothesized that lipids can be controlled as well in diabetic as in nondiabetic recipients.
  
  
  METHODS
  We compared lipid levels up to 2 years after KTX (n=192) between diabetic and nondiabetic recipients. The cohort was subdivided into nondiabetic (nonDM-K; n=123), type 2 (DM2-K; n=33), or type 1 diabetes after KTX (DM1-K; n=14), or type 1 after kidney-pancreas transplant (DM1-KP; n=22).
  
  
  RESULTS
  Mean age and body mass index of DM2-K were greater than the others (P<0.01), and diabetes groups had a higher pretransplant A1C than nonDM-K (P<0.001). After KTX, lipid levels were not higher in diabetic than in nondiabetic recipients, and did not increase in any group. Total and low-density lipoprotein cholesterol levels decreased in DM1-K (P<0.001), high-density lipoprotein levels decreased in DM1-KP (P=0.02), and triglyceride levels were unchanged after KTX for all groups. A1C improved in DM1-K and DM1-KP (P<0.0001). There was less improvement in lipid levels with tacrolimus-sirolimus immunosuppression than with other steroid-containing regimens (P<0.05).
  
  
  CONCLUSIONS
  Multiple mechanisms may contribute to better lipid levels in both groups as well as the lack of difference between diabetic and nondiabetic recipients compared with what has been reported previously: greater use of and more effective lipid-lowering agents, no significant weight gain, no difference in renal function between groups, and better control of glucose in the diabetic group. Thus, overall, lipids can be controlled as well in diabetic as in nondiabetic KTX recipients.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198-3020, USA.
authors.forename: Vijay
authors.initials: V
authors.lastname: Shivaswamy
authors.forename: R Brian
authors.initials: RB
authors.lastname: Stevens
authors.forename: Ramona
authors.initials: R
authors.lastname: Zephier
authors.forename: Myhra
authors.initials: M
authors.lastname: Zephier
authors.forename: Junfeng
authors.initials: J
authors.lastname: Sun
authors.forename: Gerald
authors.initials: G
authors.lastname: Groggel
authors.forename: Judi
authors.initials: J
authors.lastname: Erickson
authors.forename: Jennifer
authors.initials: J
authors.lastname: Larsen
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000601:surgery*; D050171:Dyslipidemias / Q000188:drug therapy* / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000276:immunology; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D007166:Immunosuppressive Agents; D008055:Lipids; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol